Evidence map›Paper›PMID 41865396›Full record

Observational studyAmerican journal of clinical pathology2026

A combination of 2 rapid immunoassays significantly improves diagnostic sensitivity for heparin-induced thrombocytopenia.

Giulia Ciarrocca Taranta, Angela Rogolino, Alessia Bertelli, Andrea Sorrentino, Michela Di Gioia, Francesca Cesari, Betti Giusti, Elena Sticchi, Martina Berteotti, Anna Maria Gori and 1 more

Abstract readObservational Study
In one paragraph

Observational study in American journal of clinical pathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Giulia Ciarrocca TarantaDepartment of Experimental and Clinical Medicine, University of Florence, Florence, Italy.ORCID 0000-0003-4339-652X
Angela RogolinoAtherothrombotic Diseases, "Careggi" University Hospital, Florence, Italy.
Alessia BertelliDepartment of Experimental and Clinical Medicine, University of Florence, Florence, Italy.ORCID 0000-0003-2482-6045
Andrea SorrentinoDepartment of Experimental and Clinical Medicine, University of Florence, Florence, Italy.ORCID 0009-0002-6969-8139
Michela Di GioiaAtherothrombotic Diseases, "Careggi" University Hospital, Florence, Italy.
Francesca CesariAtherothrombotic Diseases, "Careggi" University Hospital, Florence, Italy.ORCID 0000-0002-3616-6219
Betti GiustiDepartment of Experimental and Clinical Medicine, University of Florence, Florence, Italy.ORCID 0000-0002-8708-9444
Elena SticchiDepartment of Experimental and Clinical Medicine, University of Florence, Florence, Italy.ORCID 0000-0002-0990-4618
Martina BerteottiDepartment of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
Anna Maria GoriDepartment of Experimental and Clinical Medicine, University of Florence, Florence, Italy.ORCID 0000-0001-6857-5861
Rossella MarcucciDepartment of Experimental and Clinical Medicine, University of Florence, Florence, Italy.ORCID 0000-0001-9549-7176

Funding

IgG-specific CLIA PF4-HInstrumentation Laboratory
6 · The paper itself

Abstract

objectivesTo evaluate the diagnostic performance of chemiluminescent immunoassay (CLIA), latex immunoturbidimetric assay (LIA), and the combination of CLIA/LIA with respect to the functional heparin-induced platelet aggregation (HIPA) test.

methodsAn observational retrospective study was conducted on 100 patients. All samples were initially tested with CLIA on the ACL TOP AcuStar, and then we performed LIA and CLIA tests concurrently (on the same samples on the ACL TOP 970 CL) and the HIPA test.

resultsThe CLIA test was performed on both the AcuStar and the ACL TOP 970 CL, and results were concordant: 68% of patients were negative, and 32% were positive. The HIPA test confirmed a diagnosis in 26 of 32 and identified 6 false-positive patients and 1 false-negative patient. The LIA test was performed on the ACL TOP 970 CL: 64% of patients were negative, and the remaining 36% were positive. The HIPA test confirmed a diagnosis in 24 patients and identified 12 false-positive and 3 false-negative patients. The combination of CLIA and LIA tests allowed us to categorize 27 true-positive, 13 false-positive, 0 false-negative, and 60 true-negative patients.

conclusionsThe combination of CLIA/LIA provides high sensitivity with a progressively greater probability of detecting platelet-activating antibodies with a higher assay reactivity, reaching 100% when both automated assays yield moderate or strong results.

Indexed as

AnticoagulantsHeparinThrombocytopeniaAdultAgedAged, 80 and overFemaleHumansImmunoassayImmunoturbidimetryLuminescent MeasurementsMaleMiddle AgedPlatelet AggregationRetrospective StudiesSensitivity and SpecificityAnticoagulantsHeparindiagnosisheparin-induced platelet aggregation testimmunoassaythrombocytopeniathrombosis

Identifiers

PMID41865396
PMCPMC13017138

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.